Thus, in cases of B-ALL where BCR::ABL1 testing can enable suitable drug therapy and minimal residual disease measurement, the concurrent use of BCR::ABL1 RT-PCR is deemed essential. Here, ABL1 is linked to acute lymphoblastic leukemia.